drugs for teh management of ptsd
I'll look up the medical library skill first, then search for PTSD pharmacotherapy.
Reading File
Now I'll search the library and PubMed in parallel.
Finding Sources
Searching PubMed
"post-traumatic stress disorder"[MeSH Terms] AND "drug therapy"[MeSH Terms]
Finding Sources
Searching PubMed
"PTSD" AND "pharmacotherapy"
Good. The Maudsley Prescribing Guidelines has a dedicated PTSD section. Let me read it along with other relevant content.
Reading File
Finding Sources
The Maudsley Box 3.8 looks like the main pharmacotherapy table. Let me read that section in full.
Reading File
Finding Sources
I can see Box 3.8 in the Maudsley is at line 3739. Let me read the full PTSD box directly.
Reading File
Finding Sources
Excellent - I now have very comprehensive information. Let me also read the Harrison's section on PTSD stress disorders for completeness.
Reading File
I now have comprehensive data from multiple authoritative sources. Here is the full answer:
Pharmacological Management of PTSD
Psychotherapy (trauma-focused CBT, EMDR, prolonged exposure) is the cornerstone of PTSD treatment. Drugs are adjuncts - used when psychotherapy is unavailable, refused, or insufficient, and to target specific symptom clusters and comorbidities.
First-Line Drugs
| Drug | Key Points |
|---|---|
| Sertraline (SSRI) | FDA-approved for PTSD; preferred SSRI |
| Paroxetine (SSRI) | FDA-approved for PTSD; preferred SSRI |
| Fluoxetine (SSRI) | Preferred SSRI; well-supported evidence |
| Venlafaxine MR (SNRI) | Recommended by NICE; 35-300 mg/day; supported by multiple meta-analyses |
All SSRIs/SNRIs should be started at low doses (they can initially exacerbate anxiety) and titrated up to maximum licensed doses before declaring failure.
Second-Line Drugs
Antidepressants
- Mirtazapine 15-45 mg/day - NICE recommended; second most effective drug in a network meta-analysis; particularly useful for sleep/nightmares
- Tricyclics (TCAs) - supported by systematic review and meta-analysis:
- Amitriptyline 50-300 mg/day (NICE recommended)
- Imipramine 50-300 mg/day
- Note: best TCA evidence is for desipramine, but it is not widely available
- Phenelzine (MAOI) 15-75 mg/day - ranked the most effective drug in one network meta-analysis; reserved for refractory cases due to dietary restrictions and drug interactions
Antipsychotics (target intrusion symptoms - flashbacks and nightmares - but generally NOT avoidance or hyperarousal):
- Olanzapine 5-20 mg - may be most effective among antipsychotics
- Quetiapine 50-800 mg - more robust evidence than risperidone; NICE-mentioned
- Risperidone 0.5-6 mg - specifically mentioned by NICE
Alpha-1 blocker
- Prazosin 2-15 mg at night - specifically targets PTSD-related nightmares and sleep disturbance; start at 1 mg at night and titrate slowly to minimize orthostatic hypotension
Emerging / Investigational
| Drug | Status |
|---|---|
| Ketamine IV | Rapid reduction in symptom severity; growing acute and chronic efficacy data |
| MDMA-assisted psychotherapy | Phase III trials completed for severe/refractory PTSD; acts as adjunct to intensive psychotherapy (not standalone) |
| Duloxetine | Two small open studies show efficacy |
| Topiramate | Reduces intrusion and avoidance; evidence from Harrison's |
| Stellate ganglion block | Procedural intervention showing emerging efficacy |
What to Avoid / Use with Caution
- Benzodiazepines - useful only for short-term crisis management; should not be given in the immediate aftermath of trauma (may worsen PTSD outcomes)
- Escitalopram, hydrocortisone, intranasal oxytocin given acutely post-trauma to prevent PTSD have shown equivocal results
Symptom-Targeted Summary
| Symptom cluster | Preferred drug(s) |
|---|---|
| Overall PTSD (all clusters) | SSRIs, venlafaxine |
| Nightmares / sleep disturbance | Prazosin, mirtazapine, trazodone (low dose) |
| Intrusion / flashbacks | Antipsychotics (adjunct) |
| Refractory / severe | Phenelzine, MAOI, ketamine |
| Comorbid depression | SSRIs, mirtazapine, TCAs |
Notable 2025 Trial (PubMed)
A Phase III RCT published in JAMA Psychiatry (2025) evaluated brexpiprazole + sertraline as a combination in PTSD [PMID: 39693081], suggesting adjunctive atypical antipsychotics continue to be explored as augmentation strategies.
Sources:
- The Maudsley Prescribing Guidelines in Psychiatry, 15th ed., Box 3.8 (PTSD)
- Harrison's Principles of Internal Medicine, 22nd ed., Chapter on Stress Disorders
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry (anxiety/PTSD pharmacology)
- Stahl's Essential Psychopharmacology, PTSD chapter
Create a quick reference comparing first-line PTSD drugs
Asking for Preferences
What format would you like for the quick reference?
Here is the quick reference:
First-Line PTSD Drugs - Quick Reference
| Drug | Class | FDA Approved for PTSD | Usual Dose | Key Advantages | Key Disadvantages | Start Low? |
|---|---|---|---|---|---|---|
| Sertraline | SSRI | Yes | 50-200 mg/day | Best-evidenced; safe in comorbidities; once daily | Sexual dysfunction; initial anxiety worsening; GI upset | Yes - start 25 mg |
| Paroxetine | SSRI | Yes | 20-60 mg/day | FDA-approved; sedating (helps sleep) | Worst discontinuation syndrome of SSRIs; weight gain; anticholinergic effects | Yes - start 10 mg |
| Fluoxetine | SSRI | No (off-label) | 20-60 mg/day | Long half-life - fewer missed-dose effects; no discontinuation syndrome | More activating (can worsen hyperarousal initially); drug interactions (CYP2D6) | Yes - start 10 mg |
| Venlafaxine MR | SNRI | No (off-label) | 75-300 mg/day | NICE-recommended; dual NE+5HT action; useful for comorbid depression/pain | Dose-dependent hypertension; discontinuation syndrome; nausea | Yes - start 37.5 mg |
At a Glance - Symptom Coverage
| Symptom Domain | Sertraline | Paroxetine | Fluoxetine | Venlafaxine MR |
|---|---|---|---|---|
| Re-experiencing / intrusions | + | + | + | + |
| Avoidance | + | + | + | + |
| Hyperarousal | + | + | + | + |
| Sleep / nightmares | Moderate | Moderate (sedating) | Low | Moderate |
| Comorbid depression | + | + | + | ++ |
| Comorbid anxiety | + | + | + | ++ |
Practical Notes
- All four should be trialed for at least 8-12 weeks at adequate dose before switching.
- Start at half the target dose - SSRIs/SNRIs can transiently worsen anxiety in the first 1-2 weeks.
- If nightmares persist on any of these, add prazosin at night (2-15 mg) rather than switching.
- Sertraline is generally the default first choice given its FDA approval, tolerability profile, and the breadth of evidence.
- Venlafaxine MR is the preferred option when there is prominent comorbid depression or a prior SSRI failure.
- Paroxetine's sedating profile can be useful in patients with marked sleep disruption, but its withdrawal syndrome requires slow tapering.
Sources: Maudsley Prescribing Guidelines 15th ed., NICE Guidelines, Harrison's 22nd ed.
This is a shared conversation. Sign in to Orris to start your own chat.